Tag: pathologicCompResponse

Pathologic complete response: Or pathological complete response. No remaining microscopic evidence of viable cancer cells in tissue biopsied after breast cancer treatment.

News

11/19/12
08/01/11
06/02/11

Studies

  • Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer Cite
    Katayama A, Miligy IM, Shiino S, Toss MS, Eldib K, Kurozumi S, et al. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Modern Pathology. Springer Science and Business Media LLC; 2021; 10.1038/s41379-021-00738-5
  • Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer Cite
    Woo J, Ryu JM, Jung SM, Choi HJ, Lee SK, Yu J, et al. Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer. European Journal of Surgical Oncology. Elsevier BV; 2020; 10.1016/j.ejso.2020.08.023
  • The Tumor–Fat Interface Volume of Breast Cancer on Pretreatment MRI Is Associated with a Pathologic Response to Neoadjuvant Chemotherapy Cite
    Cho H, Park M, Park H, Ko ES, Hwang NY, Im Y, et al. The Tumor–Fat Interface Volume of Breast Cancer on Pretreatment MRI Is Associated with a Pathologic Response to Neoadjuvant Chemotherapy. Biology. MDPI AG; 2020; 9:391 10.3390/biology9110391
  • Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial Cite
    Di Cosimo S, Porcu L, Agbor-tarh D, Cinieri S, Franzoi MA, De Santis MC, et al. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Research. Springer Science and Business Media LLC; 2020; 22 10.1186/s13058-020-01356-w
  • Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? Cite
    Lai V, Hajjaj O, Le D, Shokoohi A, Chia S, Simmons C. Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 184:755-762 10.1007/s10549-020-05894-x
  • Risk Factors for Ipsilateral Breast Tumor Recurrence in Triple-Negative or HER2-Positive Breast Cancer Patients Who Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy Cite
    Ishitobi M, Matsuda N, Tazo M, Nakayama S, Tokui R, Ogawa T, et al. Risk Factors for Ipsilateral Breast Tumor Recurrence in Triple-Negative or HER2-Positive Breast Cancer Patients Who Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 10.1245/s10434-020-09176-0
  • Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment? Cite
    Alan O, Akin Telli T, Aktas B, Koca S, Ökten IN, Hasanov R, et al. Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?. World Journal of Surgical Oncology. Springer Science and Business Media LLC; 2020; 18 10.1186/s12957-020-02019-y
  • Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial Cite
    de Groot S, Lugtenberg RT, Cohen D, Welters MJP, Ehsan I, Vreeswijk MPG, et al. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nature Communications. Springer Science and Business Media LLC; 2020; 11 10.1038/s41467-020-16138-3
  • Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor‐positive breast cancer patients Cite
    Boland MR, Ryan ÉJ, Nugent T, Gilroy D, Kelly ME, Kennedy J, et al. Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor‐positive breast cancer patients. Journal of Surgical Oncology. Wiley; 2020; 10.1002/jso.26096
  • Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients Cite
    Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, et al. Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer. Korean Breast Cancer Society; 2020; 23:259 10.4048/jbc.2020.23.e34
  • Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy Cite
    Hamy A, Darrigues L, Laas E, De Croze D, Topciu L, Lam G, et al. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLOS ONE. Public Library of Science (PLoS); 2020; 15:e0234191 10.1371/journal.pone.0234191
  • Risk factors of ipsilateral breast tumor recurrence in triple-negative or HER2-positive breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy. Cite
    Tazo M, Kojima Y, Yoshida A, Nakayama S, Tokui R, Ogawa T, et al. Risk factors of ipsilateral breast tumor recurrence in triple-negative or HER2-positive breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:e12599-e12599 10.1200/jco.2020.38.15_suppl.e12599
  • Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation Cite
    Keilty D, Nezafat Namini S, Swain M, Maganti M, Cil TD, McCready DR, et al. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2020; 108:676-685 10.1016/j.ijrobp.2020.04.044
  • Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials Cite
    Werutsky G, Untch M, Hanusch C, Fasching PA, Blohmer J, Seiler S, et al. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. European Journal of Cancer. Elsevier BV; 2020; 130:92-101 10.1016/j.ejca.2020.02.015
  • Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy Cite
    Samiei S, van Nijnatten TJA, de Munck L, Keymeulen KBMI, Simons JM, Kooreman LFS, et al. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2020; 271:574-580 10.1097/sla.0000000000003126
  • Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis Cite
    Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clinical Cancer Research. American Association for Cancer Research (AACR); 2020; 26:2838-2848 10.1158/1078-0432.ccr-19-3492
  • Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis Cite
    Yau C, van der Noordaa M, Wei J, Osdoit M, Reyal F, Hamy A, et al. Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis. General Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-gs5-01
  • Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01) Cite
    Stankowski-Drengler TJ, Schumacher JR, Hanlon B, Livingston-Rosanoff D, Van de Walle K, Greenberg CC, et al. Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01). Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 27:637-644 10.1245/s10434-019-07846-2
  • Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort Cite
    Díaz‐Casas SE, Castilla‐Tarra JA, Pena‐Torres E, Orozco‐Ospino M, Mendoza‐Diaz S, Nuñez‐Lemus M, et al. Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort. The Oncologist. Wiley; 2019; 24 10.1634/theoncologist.2019-0300
  • Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy Cite
    Asaoka M, Narui K, Suganuma N, Chishima T, Yamada A, Sugae S, et al. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy. European Journal of Surgical Oncology. Elsevier BV; 2019; 45:2289-2294 10.1016/j.ejso.2019.08.001
  • Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response Cite
    Hassinger TE, Berger AC, Christopher A, Knisely AT, Mehaffey JH, Brenin DR, et al. Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response. Journal of Surgical Research. Elsevier BV; 2020; 247:52-58 10.1016/j.jss.2019.10.043
  • Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option? Cite
    Özkurt E, Sakai T, Wong SM, Tukenmez M, Golshan M. Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 26:3260-3268 10.1245/s10434-019-07534-1
  • Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials Cite
    Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer J, Seiler S, et al. Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials. Annals of Oncology. Elsevier BV; 2019; 30:v62-v63 10.1093/annonc/mdz240.014
  • Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database Cite
    Bagegni NA, Tao Y, Ademuyiwa FO. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. PLOS ONE. Public Library of Science (PLoS); 2019; 14:e0222358 10.1371/journal.pone.0222358
  • A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators Cite
    Zhang F, Huang M, Zhou H, Chen K, Jin J, Wu Y, et al. A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 26:3912-3919 10.1245/s10434-019-07655-7
  • Impact of serum vitamin D on the response and the prognosis in breast cancer patients treated with neoadjuvant chemotherapy. Cite
    Tokunaga E, Masuda T, Ijichi H, Koga C, Tajiri W, Tanaka J, et al. Impact of serum vitamin D on the response and the prognosis in breast cancer patients treated with neoadjuvant chemotherapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:e12088-e12088 10.1200/jco.2019.37.15_suppl.e12088
  • Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice Cite
    Saw S, Lim J, Lim SH, Wong M, Lim C, Yap YS. Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 177:197-206 10.1007/s10549-019-05290-0
  • Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer Cite
    Usiskin I, Li F, Irwin ML, Cartmel B, Sanft T. Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2019; 26:719-728 10.1007/s12282-019-00974-3
  • Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer Cite
    van Uden DJP, van Maaren MC, Bult P, Strobbe LJA, van der Hoeven JJM, Blanken-Peeters CFJM, et al. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 176:217-226 10.1007/s10549-019-05219-7
  • Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy Cite
    Wang X, He Y, Fan Z, Wang T, Xie Y, Li J, et al. Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy. Breast Care. S. Karger AG; 2019; 14:388-393 10.1159/000495186
  • Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy Cite
    Goto W, Kashiwagi S, Takada K, Asano Y, Takahashi K, Fujita H, et al. Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy. Journal of Translational Medicine. Springer Science and Business Media LLC; 2018; 16 10.1186/s12967-018-1679-0
  • Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma Cite
    Resende U, Cabello C, Oliveira Botelho Ramalho S, Zeferino L. Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma. Oncology. S. Karger AG; 2018; 95:229-238 10.1159/000489785
  • Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response Cite
    Kozak MM, Jacobson CE, von Eyben R, Pollom EL, Telli M, Horst KC. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2018; 16:845-850 10.6004/jnccn.2018.7022
  • High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy Cite
    Fujimoto Y, Higuchi T, Nishimukai A, Miyagawa Y, Kira A, Ozawa H, et al. High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy. Journal of Surgical Oncology. Wiley; 2018; 118:228-237 10.1002/jso.25125
  • Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes Cite
    Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, et al. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 171:501-511 10.1007/s10549-018-4853-4
  • Ki67 to predict RCB0/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34. Cite
    Singer CF, Rudas M, Fesl C, Steger GG, Pfeiler G, Egle D, et al. Ki67 to predict RCB0/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:589-589 10.1200/jco.2018.36.15_suppl.589
  • Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy Cite
    Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, et al. Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy. American Journal of Clinical Pathology. Oxford University Press (OUP); 2018; 150:34-42 10.1093/ajcp/aqy028
  • Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy Cite
    Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 170:559-567 10.1007/s10549-018-4801-3
  • Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer Cite
    Chiba A, Raman R, Thomas A, Lamy P, Viala M, Pouderoux S, et al. Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2018; 18:144-149 10.1016/j.clbc.2017.12.001
  • Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer Cite
    Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, et al. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2017; 15:1216-1223 10.6004/jnccn.2017.0158
  • Young Women Who Achieve Pathologic Complete Response in the Axillary Lymph Nodes Do Not Have Improved Survival Compared to Those Who Remain Lymph Node Positive after Neoadjuvant Chemotherapy Cite
    Kozak M, Jacobson C, Horst K. Young Women Who Achieve Pathologic Complete Response in the Axillary Lymph Nodes Do Not Have Improved Survival Compared to Those Who Remain Lymph Node Positive after Neoadjuvant Chemotherapy. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2017; 99:E26 10.1016/j.ijrobp.2017.06.653
  • Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer Cite
    Chen VE, Gillespie EF, Zakeri K, Murphy JD, Yashar CM, Lu S, et al. Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer. Advances in Radiation Oncology. Elsevier BV; 2017; 2:105-109 10.1016/j.adro.2017.01.012
  • Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial Cite
    Kimbung S, Markholm I, Bjöhle J, Lekberg T, von Wachenfeldt A, Azavedo E, et al. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. International Journal of Cancer. Wiley; 2017; 142:618-628 10.1002/ijc.31070
  • Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers Cite
    Monneur A, Goncalves A, Gilabert M, Finetti P, Tarpin C, Zemmour C, et al. Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers. Oncotarget. Impact Journals, LLC; 2017; 8:66019-66032 10.18632/oncotarget.19732
  • Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials Cite
    van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, et al. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 167:59-71 10.1007/s10549-017-4480-5
  • Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy Cite
    Petruolo OA, Pilewskie M, Patil S, Barrio AV, Stempel M, Wen HY, et al. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2556-2562 10.1245/s10434-017-5898-z
  • Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer Cite
    Hage AN, Capriccioso C, Brennan J, Heiden B, Zheutlin A, Sabel MS. Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer. Journal of Surgical Oncology. Wiley; 2017; 116:665-670 10.1002/jso.24721
  • The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer Cite
    Nakhlis F, Regan MM, Warren LE, Bellon JR, Hirshfield-Bartek J, Duggan MM, et al. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2563-2569 10.1245/s10434-017-5903-6
  • Abstract P6-09-24: Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer Cite
    Thomas A, Thezenas S, Mott S, Raman R, Viala M, Pouderoux S, et al. Abstract P6-09-24: Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p6-09-24
  • Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) Cite
    Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:1061-1069 10.1200/jco.2016.69.4406
  • Outcome after neoadjuvant chemotherapy in Asian breast cancer patients Cite
    Lim LY, Miao H, Lim JSJ, Lee SC, Bhoo-Pathy N, Yip CH, et al. Outcome after neoadjuvant chemotherapy in Asian breast cancer patients. Cancer Medicine. Wiley; 2016; 6:173-185 10.1002/cam4.985
  • Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis Cite
    Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, et al. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLOS Medicine. Public Library of Science (PLoS); 2016; 13:e1002193 10.1371/journal.pmed.1002193
  • Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy Cite
    Kasimir-Bauer S, Bittner A, König L, Reiter K, Keller T, Kimmig R, et al. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Research. Springer Science and Business Media LLC; 2016; 18 10.1186/s13058-016-0679-3
  • Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Cite
    Jung YY, Hyun CL, Jin M, Park IA, Chung YR, Shim B, et al. Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Journal of Breast Cancer. Korean Breast Cancer Society; 2016; 19:261 10.4048/jbc.2016.19.3.261
  • Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database Cite
    Liu J, Chen K, Jiang W, Mao K, Li S, Kim MJ, et al. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. Journal of Cancer Research and Clinical Oncology. Springer Science and Business Media LLC; 2016; 143:161-168 10.1007/s00432-016-2281-6
  • Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426) Cite
    Warner ET, Ballman KV, Strand C, Boughey JC, Buzdar AU, Carey LA, et al. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 159:109-118 10.1007/s10549-016-3918-5
  • Effect of Body Mass Index– and Actual Weight–Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer Cite
    Raman R, Mott SL, Schroeder MC, Phadke S, El Masri J, Thomas A. Effect of Body Mass Index– and Actual Weight–Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:480-486 10.1016/j.clbc.2016.06.008
  • Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer Cite
    De Iuliis F, Salerno G, Corvino R, D'Aniello D, Cefalì K, Taglieri L, et al. Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2017; 17:34-40 10.1016/j.clbc.2016.06.010
  • Effect of Body Mass Index– and Actual Weight–Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer Cite
    Raman R, Mott SL, Schroeder MC, Phadke S, El Masri J, Thomas A. Effect of Body Mass Index– and Actual Weight–Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:480-486 10.1016/j.clbc.2016.06.008
  • Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes Cite
    Volders J, Haloua M, Krekel N, Negenborn V, Barbé E, Sietses C, et al. Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2016; 42:986-993 10.1016/j.ejso.2016.02.252
  • Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy Cite
    Baron P, Beitsch P, Boselli D, Symanowski J, Pellicane JV, Beatty J, et al. Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2015; 23:1522-1529 10.1245/s10434-015-5030-1
  • Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer – a Single Centre Study. (PPLB – 01) Cite
    Agrawal S, Banswal L, Saha A, Arun I, Datta SS, Chatterjee S, et al. Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer – a Single Centre Study. (PPLB – 01). Indian Journal of Surgical Oncology. Springer Science and Business Media LLC; 2016; 7:397-406 10.1007/s13193-016-0523-3
  • Parsing Pathologic Complete Response in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer Cite
    Morrow M. Parsing Pathologic Complete Response in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2016; 2:516 10.1001/jamaoncol.2015.4919
  • Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands Cite
    Vugts G, Maaskant-Braat A, de Roos W, Voogd A, Nieuwenhuijzen G. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2016; 42:956-964 10.1016/j.ejso.2016.03.023
  • Abstract P6-12-06: Preoperative chemotherapy regimens and breast cancer subtype in an underinsured Hispanic population Cite
    Mehta D, Winton L, Walters J, Hsu C, Nodora J, Martinez M, et al. Abstract P6-12-06: Preoperative chemotherapy regimens and breast cancer subtype in an underinsured Hispanic population. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p6-12-06
  • Abstract P5-08-48: Vitamin D deficiency in various breast cancer subtypes and its impact on response to neoadjuvant chemotherapy in operable breast cancer Cite
    Raman R, Link B, Mott S, Schroeder M, Thomas A. Abstract P5-08-48: Vitamin D deficiency in various breast cancer subtypes and its impact on response to neoadjuvant chemotherapy in operable breast cancer. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p5-08-48
  • High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer Cite
    Alba E, Lluch A, Ribelles N, Anton‐Torres A, Sanchez‐Rovira P, Albanell J, et al. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. The Oncologist. Wiley; 2016; 21:150-155 10.1634/theoncologist.2015-0312
  • Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer Cite
    Korn E, Sachs M, McShane L. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer. Annals of Oncology. Elsevier BV; 2016; 27:10-15 10.1093/annonc/mdv507
  • Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry Cite
    Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry. Annals of Oncology. Elsevier BV; 2016; 27:480-487 10.1093/annonc/mdv611
  • Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base Cite
    Killelea BK, Yang VQ, Wang S, Hayse B, Mougalian S, Horowitz NR, et al. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:4267-4276 10.1200/jco.2015.63.7801
  • Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy Cite
    Baulies S, Belin L, Mallon P, Senechal C, Pierga J, Cottu P, et al. Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy. British Journal of Cancer. Springer Science and Business Media LLC; 2015; 113:30-36 10.1038/bjc.2015.174
  • Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer Cite
    Kim T, Han W, Kim MK, Lee JW, Kim J, Ahn SK, et al. Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. Journal of Breast Cancer. Korean Breast Cancer Society; 2015; 18:16 10.4048/jbc.2015.18.1.16
  • Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer Cite
    Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, et al. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. Annals of Oncology. Elsevier BV; 2015; 26:523-528 10.1093/annonc/mdu559
  • Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer Cite
    Horimoto Y, Arakawa A, Tanabe M, Sonoue H, Igari F, Senuma K, et al. Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2014; 14 10.1186/1471-2407-14-550
  • Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Cite
    Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer. Korean Breast Cancer Society; 2014; 17:40 10.4048/jbc.2014.17.1.40
  • Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial Cite
    Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E, et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Annals of Oncology. Elsevier BV; 2014; 25:1128-1136 10.1093/annonc/mdu118
  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Cite
    Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet. Elsevier BV; 2014; 384:164-172 10.1016/s0140-6736(13)62422-8
  • Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer Cite
    Kim M, Allen P, Gonzalez-Angulo A, Woodward W, Meric-Bernstam F, Buzdar A, et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Annals of Oncology. Elsevier BV; 2013; 24:1999-2004 10.1093/annonc/mdt131
  • Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27 Cite
    Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE, et al. Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:3960-3966 10.1200/jco.2011.40.8369
  • Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy Cite
    Ju NR, Jeffe DB, Keune J, Aft R. Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 137:195-201 10.1007/s10549-012-2312-1
  • Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab Cite
    Ohzawa H, Sakatani T, Niki T, Yasuda Y, Hozumi Y. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab. Breast Cancer. Springer Science and Business Media LLC; 2012; 21:563-570 10.1007/s12282-012-0424-4
  • Neoadjuvant chemotherapy in breast cancer—insights from the German experience Cite
    von Minckwitz G. Neoadjuvant chemotherapy in breast cancer—insights from the German experience. Breast Cancer. Springer Science and Business Media LLC; 2012; 19:282-288 10.1007/s12282-012-0393-7
  • Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study Cite
    Guiu S, Arnould L, Bonnetain F, Dalban C, Favier L, Desmoulins I, et al. Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study. The Breast. Elsevier BV; 2013; 22:301-308 10.1016/j.breast.2012.07.012
  • Obesity or Overweight Is Associated with Worse Pathological Response to Neoadjuvant Chemotherapy among Chinese Women with Breast Cancer Cite
    Chen S, Chen C, Zhou Y, Zhou R, Yu K, Shao Z. Obesity or Overweight Is Associated with Worse Pathological Response to Neoadjuvant Chemotherapy among Chinese Women with Breast Cancer. PLoS ONE. Public Library of Science (PLoS); 2012; 7:e41380 10.1371/journal.pone.0041380
  • Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy. Cite
    Pirvulescu C, Loibl S, Von Minckwitz G, Mau C, Blohmer JU, Costa SD, et al. Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:541-541 10.1200/jco.2012.30.15_suppl.541
  • Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy Cite
    Tsunashima R, Naoi Y, Kishi K, Baba Y, Shimomura A, Maruyama N, et al. Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy. Cancer Letters. Elsevier BV; 2012; 324:42-47 10.1016/j.canlet.2012.04.017
  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Cite
    Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Elsevier BV; 2012; 379:633-640 10.1016/s0140-6736(11)61847-3
  • Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients Cite
    Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. European Journal of Cancer. Elsevier BV; 2011; 47:2084-2090 10.1016/j.ejca.2011.06.014
  • Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials Cite
    von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 125:145-156 10.1007/s10549-010-1228-x
  • Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Cite
    Sánchez-Muñoz A, García-Tapiador AM, Martínez-Ortega E, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, et al. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clinical and Translational Oncology. Springer Science and Business Media LLC; 2008; 10:646-653 10.1007/s12094-008-0265-y